Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders
Study Details
Study Description
Brief Summary
This is a single center, open prospective study to evaluate the effectiveness of quetiapine monotherapy in the maintenance treatment of adolescent patients with a bipolar spectrum disorder (bipolar I and bipolar II disorders, cyclothymia, and bipolar disorder not otherwise specified [bipolar NOS]) for a minimum of 48 weeks. Patients will be screened (enrolment phase) either when already stabilized or during an acute episode of mania/hypomania or depression.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Study Design
Outcome Measures
Primary Outcome Measures
- Proportion of treated study patients maintained on monotherapy for the duration of the trial compared to the proportion requiring systematic adjunctive medication. []
Secondary Outcome Measures
- Time to an episode recurrence (Montgomery-Asberg Depression Rating Scale []
- /Young Mania Rating Scale [MADRS/YMRS] > 15) []
- Time to hospitalization []
- Autobiographical Memory Interview (AMI) mean score over treatment []
- Clinical Global Impression-Bipolar Disorder (CGI-BP) score during treatment and at study completion []
- YMRS total score during treatment and at study completion []
- MADRS total score during treatment and at study completion []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Provide written informed consent before initiation of any study-related procedures.
-
A lifetime diagnosis of bipolar spectrum disorder: bipolar I and bipolar II disorders, cyclothymia, bipolar NOS, as defined by the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV).
-
Male or female, between the ages of 12 and 20 years at enrolment.
-
No preventive treatment at least one month prior to enrolment.
-
Female patients of childbearing potential and who are sexually active must be using a reliable method of contraception. Reliable methods of contraception include hormonal contraceptives (e.g., oral contraceptive or long-term injectable or implantable hormonal contraceptive), double-barrier methods (e.g., condom and diaphragm, condom and foam, condom and sponge), intrauterine devices, and tubal ligation.
-
Able to understand and comply with the requirements of the study.
Exclusion Criteria:
-
Known intolerance or lack of response to quetiapine fumarate as judged by the investigator.
-
Pregnancy or lactation. Female patients of childbearing potential must have a negative urine human chorionic gonadotropin (HCG) test at enrolment.
-
History of substance or alcohol dependence within three months of enrolment (except for caffeine or nicotine dependence), as defined by DSM-IV criteria.
-
Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrolment.
-
Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, and saquinavir. Should a new drug be started, investigators will consult the pharmacy as this list is not exhaustive.
-
Use of any of the following cytochrome P450 inducers in the 14 days preceding enrolment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids.
-
Current use of fluvoxamine, nefazodone, or grapefruit juice.
-
Thyroid stimulating hormone (TSH) concentration outside of the normal range.
-
Unstable or inadequately treated medical illness (e.g., diabetes, angina pectoris, hypertension) as judged by the investigator.
-
History of hepatic disease, or elevated hepatic enzymes at entry testing.
-
Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment.
-
Use of an experimental drug within 30 days of enrolment.
-
Previous trials of maintenance therapy.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Mood Disorders Center of Ottawa | Ottawa | Ontario | Canada | K1G 4G3 |
Sponsors and Collaborators
- Mood Disorders Center of Ottawa
- AstraZeneca
Investigators
- Principal Investigator: Paul Grof, M.D., Mood Disorders Center of Ottawa
- Principal Investigator: Anne Duffy, M.D., Mood Disorders Center of Ottawa
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- D1441L00024